A Common Requirement for the Catalytic Activity and Both SH2 Domains of SHP-2 in Mitogen-activated Protein (MAP) Kinase Activation by the ErbB Family of Receptors-Reference-Cited by-同舟云学术

A Common Requirement for the Catalytic Activity and Both SH2 Domains of SHP-2 in Mitogen-activated Protein (MAP) Kinase Activation by the ErbB Family of Receptors

Published:1998-07 Issue:27 Volume:273 Page:16643-16646
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Deb Tushar Baran,Wong Lily,Salomon David S.,Zhou Gaochao,Dixon Jack E.,Gutkind J. Silvio,Thompson Stewart A.,Johnson Gibbes R.

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference25 articles.

1. Regulation of signal transduction and signal diversity by receptor oligomerization

2. Amphiregulin induces tyrosine phosphorylation of the epidermal growth factor receptor and p185erbB2. Evidence that amphiregulin acts exclusively through the epidermal growth factor receptor at the surface of human epithelial cells.

3. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4

4. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.

5. Phosphotyrosine phosphatases with SH2 domains: regulators of signal transduction

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant Cancers;Journal of Medicinal Chemistry;2023-09-27

2. Protein tyrosine kinase 6 regulates activation of SRC kinase;Journal of Biological Chemistry;2022-11

3. Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine Phosphatase SHP2 with Anti-Breast Cancer Cell Effects;ACS Omega;2020-09-25

4. Inhibitor Binding Sites in the Protein Tyrosine Phosphatase SHP-2;Mini-Reviews in Medicinal Chemistry;2020-07-17

5. Biology, pathology, and therapeutic targeting of RAS;Advances in Cancer Research;2020